AC
APLT

Armistice Capital’s Applied Therapeutics APLT Stock Holding History

Armistice Capital’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,400,000
Closed -$8.47M – 302
2023
Q3 		$8.47M Buy
+3,400,000
New +$5.6M 0.13% 93

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Armistice Capital's APLT Position: Q4 2023 in Review

Armistice Capital sold out of Applied Therapeutics (APLT) in Q4 2023, closing a stake of 3,400,000 shares — an estimated $8.47M sold.

Armistice Capital first reported a position in APLT in Q3 2023 and held it in 1 quarter. The position peaked at $8.47M in Q3 2023. 83 funds tracked by Wall St. Rank hold APLT as of Q4 2023.

  • Armistice Capital reported no remaining Applied Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Armistice Capital sold 3,400,000 Applied Therapeutics shares in Q4 2023, an estimated $8.47M.
  • Armistice Capital first reported a position in Applied Therapeutics in Q3 2023 and held it in 1 quarter.
  • Armistice Capital's Applied Therapeutics position peaked at $8.47M in Q3 2023.
  • 83 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.